Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for CGEM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2020. Start Trial.
Date Value
June 30, 2026 -159.25M
March 31, 2026 -178.64M
December 31, 2025 -175.75M
September 30, 2025 -174.27M
June 30, 2025 -171.53M
March 31, 2025 -150.21M
December 31, 2024 -145.30M
September 30, 2024 -126.81M
June 30, 2024 -126.81M
March 31, 2024 -121.52M
December 31, 2023 -134.28M
September 30, 2023 -141.13M
Date Value
June 30, 2023 -161.34M
March 31, 2023 -155.75M
December 31, 2022 -126.66M
September 30, 2022 -116.85M
June 30, 2022 -73.05M
March 31, 2022 -63.83M
December 31, 2021 -43.43M
September 30, 2021 -37.70M
June 30, 2021 -36.22M
March 31, 2021 -26.27M
December 31, 2020 -29.77M
September 30, 2020 -25.20M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Rallybio Corp. 26.71M
MapLight Therapeutics, Inc. -174.67M
Arrowhead Pharmaceuticals, Inc. -59.06M
Oncolytics Biotech, Inc. -26.52M
Sangamo Therapeutics, Inc. -90.34M